DNA damage response deficiency signature predicts response to platinum-based therapy in ovarian cancer

L. A. Hill, J. M. Mulligan, S. Deharo, K. E. Keating, F. A. McDyer, T. S. Davison, C. Gourley, D. P. Harkin, R. D. Kennedy

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)S196-S196
Number of pages1
JournalEuropean Journal of Cancer
Volume49
Issue number2
Publication statusPublished - Sep 2013
Event17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity - Amsterdam, Netherlands
Duration: 27 Sep 201301 Oct 2013

Bibliographical note

17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity, Amsterdam, NETHERLANDS, SEP 27-OCT 01, 2013

Cite this

Hill, L. A., Mulligan, J. M., Deharo, S., Keating, K. E., McDyer, F. A., Davison, T. S., Gourley, C., Harkin, D. P., & Kennedy, R. D. (2013). DNA damage response deficiency signature predicts response to platinum-based therapy in ovarian cancer. European Journal of Cancer, 49(2), S196-S196.